ESPR Q4 2022 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$19M+22.2% YoY

Gross Profit

$15M77.9% margin

Operating Income

-$43M-225.9% margin

Net Income

-$55M-294.9% margin

EPS (Diluted)

$-0.93

QoQ Revenue Growth

-0.9%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$248M

Total Liabilities

$572M

Stockholders' Equity

-$324M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$15M	+22.2%
Gross Profit	$15M	$10M	+42.0%
Operating Income	-$43M	-$56M	+23.6%
Net Income	-$55M	-$65M	+14.8%

Revenue Segments

Product

$15M80%

Collaboration Revenue

$4M20%